https://mindmedicinelaw.com/briefing/controlled-vs-naturalistic-dosing-in-cannabis-research-evolving-standards-20261028-54914The Psychedelic Journalen2026-10-30T15:06:10.409021+00:00Controlled vs. Naturalistic Dosing in Cannabis Research: Evolving Standardscannabis research, controlled dosing, naturalistic studies, clinical trial design, regulatory science, public health policy, thc potency, hybrid study methods, fda guidance, market regulationhttps://mindmedicinelaw.com/briefing/ai-driven-multimodal-depression-detection-implications-for-psychedelic-trials-20261028-54658The Psychedelic Journalen2026-10-29T15:08:21.397363+00:00AI-Driven Multimodal Depression Detection: Implications for Psychedelic Trialsai depression detection, multimodal diagnostics, psychedelic clinical trials, explainable ai, directional causal fusion, digital health regulation, biometric monitoring, patient selection, mental health technologyhttps://mindmedicinelaw.com/briefing/psilocybin-retreats-connectedness-and-wellbeing-insights-for-public-health-polic-20261028-54657The Psychedelic Journalen2026-10-29T15:07:22.882216+00:00Psilocybin Retreats, Connectedness, and Wellbeing: Insights for Public Health Policypsilocybin retreats, connectedness, mental wellbeing, psychedelic research, public health policy, naturalistic study, integration, regulatory implications, mystical experienceshttps://mindmedicinelaw.com/briefing/genome-analysis-of-gymnopilus-dilepis-illuminates-psilocybin-pathways-20261028-54659The Psychedelic Journalen2026-10-29T15:07:06.122978+00:00Genome Analysis of Gymnopilus dilepis Illuminates Psilocybin Pathwayspsilocybin biosynthesis, gymnopilus dilepis genome, synthetic biology, amino acid metabolism, psychedelic research, clinical supply chain, metabolic engineering, regulatory sciencehttps://mindmedicinelaw.com/briefing/rhelion-s-psilocybin-supply-deal-sweden-s-clinical-trial-signals-market-shift-20261028-54656The Psychedelic Journalen2026-10-28T22:04:41.614328+00:00Rhelion’s Psilocybin Supply Deal: Sweden’s Clinical Trial Signals Market Shiftrhelion, psilocybin supply, sweden clinical trial, european psychedelic research, gmp suppliers, regulatory pathways, clinical trial infrastructure, market dynamics, controlled substances europehttps://mindmedicinelaw.com/briefing/dea-psychedelic-scheduling-challenge-us-research-and-fda-pathways-at-stake-20261028-54652The Psychedelic Journalen2026-10-28T22:04:17.511610+00:00DEA Psychedelic Scheduling Challenge: US Research and FDA Pathways at Stakedea psychedelic scheduling, legal challenge, fda breakthrough therapy, clinical trials, postpartum depression, drug policy, controlled substances, research chill effect, administrative procedure act, us drug regulationhttps://mindmedicinelaw.com/briefing/topical-ketamine-for-oral-mucositis-pain-evidence-and-gaps-in-cancer-care-20261027-54706The Psychedelic Journalen2026-10-29T15:07:48.084089+00:00Topical Ketamine for Oral Mucositis Pain: Evidence and Gaps in Cancer Caretopical ketamine, oral mucositis, chemotherapy pain, opioid-sparing, supportive cancer care, randomized controlled trials, adverse events, dosing variability, pediatric oncology, regulatory approvalhttps://mindmedicinelaw.com/briefing/feasibility-of-psychedelic-like-vr-for-ocd-multicentre-study-in-germany-and-ital-20261026-54698The Psychedelic Journalen2026-10-29T15:08:03.573790+00:00Feasibility of Psychedelic-Like VR for OCD: Multicentre Study in Germany and Italyvirtual reality, psychedelic therapy, obsessive-compulsive disorder, digital therapeutics, clinical trials, psychological flexibility, non-pharmacological interventions, regulatory implications, cybersickness, ego dissolutionhttps://mindmedicinelaw.com/briefing/trump-administration-advances-psychedelic-therapy-for-veterans-20261025-54654The Psychedelic Journalen2026-10-28T22:04:29.499037+00:00Trump Administration Advances Psychedelic Therapy for Veteransveterans, psychedelic therapy, trump administration, department of veterans affairs, mdma, psilocybin, policy, public health, clinical trials, federal regulationhttps://mindmedicinelaw.com/briefing/control-conditions-in-ivr-trials-implications-for-psychedelic-research-20261023-54699The Psychedelic Journalen2026-10-29T15:09:19.030385+00:00Control Conditions in IVR Trials: Implications for Psychedelic Researchivr control conditions, virtual placebo, psychedelic research, clinical trial design, digital therapeutics, randomized controlled trials, methodological rigor, fda guidance, mental health interventionshttps://mindmedicinelaw.com/briefing/bias-aware-meta-analysis-method-advances-psychedelic-research-synthesis-20261023-54700The Psychedelic Journalen2026-10-29T15:08:58.186175+00:00Bias-Aware Meta-Analysis Method Advances Psychedelic Research Synthesisbias-aware meta-analysis, psychedelic research, evidence synthesis, heterogeneous studies, clinical trials, regulatory policy, reproducibility, statistical methods, fixed-effect model, random-effects modelhttps://mindmedicinelaw.com/briefing/mri-guided-reverse-translational-framework-in-psychiatry-research-20261023-54714The Psychedelic Journalen2026-10-29T15:08:37.700319+00:00MRI-Guided Reverse-Translational Framework in Psychiatry Researchmri volumetric analysis, reverse translation, psychiatric research, animal models, psychedelic mechanisms, clinical trial design, brain structure, translational neurosciencehttps://mindmedicinelaw.com/briefing/psilocybin-s-biological-effects-in-parkinson-s-early-clinical-trial-insights-20261021-54989The Psychedelic Journalen2026-10-30T15:05:52.728632+00:00Psilocybin’s Biological Effects in Parkinson’s: Early Clinical Trial Insightspsilocybin, parkinson's disease, inflammation markers, mitochondrial stress, clinical trial, neurodegeneration, biomarkers, policy implications, mechanistic researchhttps://mindmedicinelaw.com/briefing/suicidality-during-intranasal-es-ketamine-analysis-of-2026-retrospective-cohort--20261021-54484The Psychedelic Journalen2026-10-28T22:04:58.744894+00:00Suicidality During Intranasal (Es)ketamine: Analysis of 2026 Retrospective Cohort Dataintranasal esketamine, suicidality, retrospective cohort study, ketamine safety, treatment-resistant depression, real-world evidence, FDA REMS, psychiatric protocols, post-marketing surveillance